• Ana María García Vicente, Esther Domínguez Ferreras, Victoria Sánchez Pérez, Víctor Manuel Poblete García, José Carlos Villa Guzmán, Fátima Jiménez Aragón, Maria Dolores Pineda Pineda, Ceferino Molino Trinidad, and Ángel Soriano Castrejón.
• Department of Nuclear Medicine, University General Hospital, Ciudad Real, Spain. angarvice@yahoo.es
• Eur J Radiol. 2013 Jun 1; 82 (6): e255-61.

PurposeEvaluate the diagnostic performance of contrast enhanced CT/PET (ceCT/PET) in the response assessment of patients with colorectal cancer liver metastases.Methods33 ce CT/PET studies of 19 patients with colorectal liver metastases were prospectively evaluated. All of them, 13 (68.4%) were males and 6 (31.6%) females. Mean age and range were 63 [42-78]. All patients were treated with neoadjuvant chemotherapy. In all cases post-therapy diagnostic confirmation of liver lesions was obtained. A ce CT PET/was obtained 1h after the injection of 370 MBq of 18F-FDG. Metabolic and morphologic studies were evaluated by two blinded nuclear physicians and radiologists respectively to assess the location, size and suspected diagnosis of lesions (benign or malignant). A combined assessment of both techniques was performed. The final diagnosis was established by histopathology or clinical/radiological follow-up greater than 6 months.ResultsA total of 120 liver lesions were identified, 115 were malignant and 5 benign. From the malignant lesions, 105 were identified with the ceCT, 44 with the PET and 109 with ceCT/PET. All of the benign lesions were correctly classified with any of the three imaging techniques. The sensitivity of PET, ceCT and ceCT/PET were of 38%, 91% and 95% respectively and the specificity was 100% in all three of the diagnostic studies.ConclusionAdministration of intravenous contrast in the PET/CT is mandatory to evaluate treatment response rate of liver metastases due to the limitations of isolated metabolic images in these cases.Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

31 keywords...

hide…